At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Circle Pharma Inc. presented their recent work on developing novel compounds that specifically target cyclin D1 while avoiding the toxicity associated with targeting cyclin D3.
Shanghai Helioson Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase-binding moiety covalently bonded to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer and autoimmune diseases.
A team of researchers at the University of British Columbia investigated the potential of radiopharmaceutical therapy based on Terbium-161 (161Tb) both in vitro and in vivo using a novel tracer, [161Tb]Tb-BL34L20S, which uses the C-X-C chemokine receptor type 4 (CXCR4)-targeting peptide BL34L20S labeled to 161Tb.
Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) binding moiety reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.
Baylor College of Medicine has disclosed proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to Bruton tyrosine kinase (BTK)-, DNA-binding protein Ikaros (IKZF1)- and Zinc finger protein Aiolos (IKZF3)-targeting moieties through a linker.
Jiangsu Vcare Pharmatech Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) targeting moiety via a linker reported to be useful for the treatment of cancer.
Zeno Management Inc. has identified antibody-drug conjugates comprising antibodies targeting inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) covalently bound to exatecan derivatives through a linker.
Elicera Therapeutics AB has received approval from the Swedish Medical Products Agency to start a phase I/II study of chimeric antibody receptor (CAR) T-cell therapy ELC-301 in patients with refractory or relapsed B-cell lymphoma.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized molecular glue compounds targeting protein cereblon (CRBN) acting as CRBN/target protein interaction inducers reported to be useful for the treatment of cancer.
